Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bupivacaine And Meloxicam · Zynrelef, HTX-011

Small molecule · Modulator of voltage-gated sodium channel, cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2) · developed by Heron Theraps

Approved FDA, May 2021
HRTX Developer
2 Registered trials

What is Bupivacaine And Meloxicam?

Bupivacaine and meloxicam is an extended-release fixed-ratio combination of a local anesthetic and a low-dose NSAID, incorporated in a bioerodible polymer. Bupivacaine blocks nerve impulse generation and conduction, while meloxicam inhibits cyclooxygenase (COX-1 and COX-2) and reduces prostaglandin synthesis. It is studied for acute postoperative pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zynrelef, HTX-011, ZYNRELEF
Drug type
Small molecule
Targets
voltage-gated sodium channel, cyclooxygenase-1 (PTGS1), cyclooxygenase-2 (PTGS2)
Mechanism
Modulator of voltage-gated sodium channel, cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2)
Pathways
prostaglandin synthesis, nerve impulse conduction
Therapy area
Oncology
Developer
Heron Theraps Inc (HRTX)
FDA status
Approved as Zynrelef (May 12, 2021), NDA211988 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05863221 Phase 4 Post Operative Pain, Acute Unknown HRTX
NCT05109312 Phase 4 Analgesia Active not recruiting HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnalgesiaBariatric Surgery CandidatePost Operative Pain, AcutePostoperative Pain

Other drugs acting on PTGS1 / PTGS2

More from Heron Theraps

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the HRTX page.

Follow HRTX, the company behind Bupivacaine And Meloxicam

See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.